Kamada Pharmaceuticals Delivers Record Financial Performance, Projects Continued Growth in 2025

Kamada Ltd., a biopharmaceutical company specializing in plasma-derived therapeutics, demonstrated remarkable financial performance in 2024 and anticipates continued growth in 2025. The company's strategic focus on rare disease treatments and global market expansion positions it for significant advancement in the coming year.

In its 2024 annual report, Kamada achieved record financial metrics, with annual revenue reaching $161 million, representing a 13% increase from the previous year. The company's net income surged 75% to $14.5 million, while cash flow from operations hit $47.6 million. These robust financial results prompted management to announce a special cash dividend of 20 cents per share.

The company's growth strategy centers on its six FDA-approved plasma-derived specialty therapies, with particular emphasis on products like KEDRAB, a human rabies immune globulin, and CYTOGAM, an immunoglobulin for preventing cytomegalovirus complications in organ transplant patients. Kamada expects 2025 revenue to range between $178 million and $182 million, representing approximately 12% year-over-year growth.

A key component of Kamada's expansion plan involves launching biosimilar products in Israel, with an anticipated portfolio generating $15-20 million in annual sales within five years. The company is also advancing a phase 3 trial for an inhaled alpha-1 antitrypsin therapy, which could address a market potentially exceeding $2 billion.

Global market expansion remains a priority, as evidenced by a recent $25 million contract to supply rabies and anti-varicella treatments in South America from 2025 to 2027. Additionally, Kamada plans to open a third plasma collection facility in San Antonio, Texas, which is expected to contribute $8-10 million annually and reduce reliance on third-party plasma suppliers.

The company's strategic approach includes actively pursuing mergers, acquisitions, and business development opportunities to complement its existing portfolio. CEO Amir London emphasized that these initiatives are designed to generate commercial and operational synergies while supporting the company's multi-year growth outlook.

Kamada's performance underscores the critical role of plasma-derived medicines in addressing rare and serious diseases. By maintaining a disciplined operational approach and focusing on innovation, the company is positioning itself for sustained success in the specialized therapeutics market.